STOCK TITAN

CORCEPT THERAPEUTICS (CORT) SEC Filings, Oct-Nov 2025

CORT NASDAQ

Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.

The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.

Rhea-AI Summary

Corcept Therapeutics (CORT) insider transaction: Chief Accounting & Technology Officer Joseph Douglas Lyon exercised 5,000 stock options at $13.56 per share on 11/03/2025 and sold 5,000 common shares the same day at a weighted average price of $73.6489. The filing notes sale prices ranged from $73.47 to $73.945 per share.

Following these transactions, he beneficially owned 10,277 shares directly. The filing also notes unvested restricted stock awards granted on 12/02/2024 (215 shares), 03/03/2025 (216 shares), 06/02/2025 (749 shares), and 09/02/2025 (200 shares), which vest 100% on the one-year anniversary of each grant, subject to conditions. The option exercised was fully exercisable and relates to a grant expiring 02/07/2030, with 16,571 derivative securities beneficially owned afterward.

The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/30/2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics (CORT) CEO and director Joseph K. Belanoff reported open‑market sales totaling 40,000 shares pursuant to a Rule 10b5‑1 trading plan adopted on November 26, 2024.

The trades occurred on November 3, 2025 (11,218 shares at $74.0786) and November 5, 2025 (14,355 at $74.196; 10,837 at $75.1372; 3,590 at $75.9777). Following these sales, 2,741,370 shares were beneficially owned indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

He has voting power over the trust shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
insider
-
Rhea-AI Summary

Corcept Therapeutics (CORT) officer Sean Maduck exercised stock options for 20,000 shares at $8.27 on 11/03/2025, then sold 20,000 shares at a weighted average price of $73.9908. The sale was made pursuant to a Rule 10b5-1 plan adopted on 09/05/2024.

After these transactions, he directly holds 7,904 shares and 261,986 stock options. Indirect holdings are 59,717 shares via the Sean and Molly Maduck Living Trust, 40,000 shares via the SNM 2025 GRAT, and 10,000 shares via Duckhill Capital, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics (CORT) reported Q3 2025 results. Net product revenue was $207.6 million, up from $182.5 million a year ago, driven by a 42.5% increase in sales volume, partly offset by a 20.2% lower average price due to higher authorized‑generic mix; an August 2025 price increase partially offset the decline. Cost of sales rose to $4.6 million, including a $1.0 million inventory write‑off.

Operating expenses expanded as the company invests behind pipeline and commercialization: R&D was $68.8 million and SG&A was $124.0 million. Income from operations fell to $10.2 million (from $46.6 million). Net income was $19.7 million versus $47.2 million, with diluted EPS of $0.16 versus $0.41. Cash, cash equivalents and marketable securities totaled $524.2 million as of September 30, 2025. Year‑to‑date, the company repurchased 2.6 million shares for $172.9 million; $11.4 million remains authorized. Shares outstanding were 105,188,217 as of October 23, 2025.

Key pipeline milestones: the FDA accepted the NDA for relacorilant in hypercortisolism with a PDUFA date of December 30, 2025, and accepted the NDA for relacorilant plus nab‑paclitaxel in platinum‑resistant ovarian cancer with a PDUFA date of July 11, 2026. A Q3 tax benefit reflected newly enacted U.S. legislation allowing immediate expensing of certain R&D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.81%
Tags
quarterly report
-
Rhea-AI Summary

Corcept Therapeutics (CORT) furnished an 8-K stating it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The release, dated November 4, 2025, is attached as Exhibit 99.1.

The information under Items 2.02 and 7.01 is furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless expressly stated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.81%
Tags
current report
-
Rhea-AI Summary

Corcept Therapeutics (CORT) director reports option exercise and sale. On 10/10/2025, the reporting person exercised 2,200 stock options at $14.08 per share and sold 2,200 shares at $87.54, both reported as direct holdings. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 1, 2024.

Following these transactions, common stock directly held was 0 shares. The filer reports 1,100 derivative securities (stock options) remaining directly owned, which are fully exercisable and carry an expiration date of 08/20/2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics (CORT) terminated its distribution services agreement with Optime Care, delivering notice on October 10, 2025, with termination effective January 8, 2026. Optime had served as a specialty pharmacy distributor for Korlym and Corcept’s authorized generic mifepristone, handling pharmacy operations, patient access, reimbursement support, claims, A/R, and reporting.

The agreement, originally dated August 4, 2017 and amended and restated April 1, 2024, had been extended through March 31, 2027 with automatic three-year renewals. Corcept previously informed Optime that, under its contractual rights, Optime’s exclusivity ended on September 15, 2025. The contract permitted termination for convenience by Corcept with 90-days advance notice, as well as customary remedies for material breach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
current report
-
Rhea-AI Summary

Corcept Therapeutics (CORT) reported a Form 144 notice for the proposed sale of 2,200 common shares with an aggregate market value of $192,588, scheduled for 10/10/2025 on NASDAQ. The filing states the shares were acquired under an option granted on 08/20/2018 and payment will be in cash. The filing also discloses three prior sales by the same seller: 2,200 shares on 07/10/2025 for $156,376, 2,200 shares on 08/11/2025 for $159,060, and 2,200 shares on 09/10/2025 for $159,390, totaling $474,826 in gross proceeds. Outstanding shares are listed as 105,371,729, making the scheduled sale a very small fraction of total shares outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.30%
Tags
other
-
Rhea-AI Summary

Insider transactions by Chief Development Officer William Guyer show simultaneous option exercise and stock sales dated 10/07/2025. Mr. Guyer exercised 20,000 stock options at an exercise price of $21.65 per share, immediately acquiring 20,000 shares. The same day he sold 20,000 shares under a Rule 10b5-1 plan for a weighted average sale price of $89.9391 per share (range $89.85–$90.18). After these transactions his reported beneficial ownership is 25,287 shares of common stock and he holds 310,000 shares underlying outstanding options exercisable through 09/01/2031. The filing was signed by an attorney-in-fact on 10/09/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.30%
Tags
insider
Rhea-AI Summary

Corcept Therapeutics Inc. reported a Rule 144 notice for the proposed sale of 20,000 common shares through Stifel Nicolaus & Company Inc. on 10/07/2025. The filing lists an aggregate market value of $1,797,000 and states 105,370,000 shares outstanding, indicating the transaction size relative to the company's issued stock. The shares were acquired the same day by stock option exercise and paid for in cash, according to the acquisition table.

The notice also discloses multiple sales by the same person, William Guyer, over the past three months: 4,379, 500, 14, 35,007, and 20,000 shares on dates from 07/17/2025 through 09/02/2025, with listed gross proceeds. The filing includes the required certification that the seller is unaware of undisclosed material adverse information at the time of the notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
other

FAQ

How many CORCEPT THERAPEUTICS (CORT) SEC filings are available on StockTitan?

StockTitan tracks 201 SEC filings for CORCEPT THERAPEUTICS (CORT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for CORCEPT THERAPEUTICS (CORT)?

The most recent SEC filing for CORCEPT THERAPEUTICS (CORT) was filed on November 13, 2026.